In the era of chemotherapy, clinical trials were done to find out what is the maximum amount of these drugs that patients could tolerate without serious side effects. This makes sense because these drugs directly kill cancer cells. But new treatments are available that work in different ways: immunotherapies work to make the immune system fight the cancer more effectively. For these drugs, more might not be better. In this session we’ll talk about how and why patients are overtreated with cancer immunotherapies, how the REFINE-Lung study aims to find the right balance and the challenges of trials which involve giving patients less treatment than the standard even if less might be better.
Speakers
Dr Ehsan Ghorani, Clinical Senior Lecturer in Medical Oncology, Department of Surgery & Cancer
For more information please contact Kelly Gleason.